- Home
- CMMB vs PPBT Comparison
CMMB vs PPBT Comparison
Compare CMMB & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMMB | PPBT |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | Israel | Israel |
| Employees | 12 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 2.4M |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CMMB | PPBT |
|---|---|---|
| Price | $2.28 | $1.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $25.00 | ★ $30.00 |
| AVG Volume (30 Days) | 123.1K | ★ 2.1M |
| Earning Date | 05-21-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.67 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $59.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $0.41 |
| 52 Week High | $3.55 | $5.18 |
Technical Indicators
Market Signals| Indicator | CMMB | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 41.39 |
| Support Level | N/A | $1.35 |
| Resistance Level | N/A | $1.85 |
| Average True Range (ATR) | 0.00 | 0.19 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 18.92 |
Price Performance
Historical ComparisonAbout CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.